Fortress Biotech: A Drug Financing Experiment Expands

Fortress Biotech has established nine subsidiary companies since 2013, each financed differently and each focused on an area of unmet need. Fortress CEO and longtime life sciences investor Lindsay Rosenwald lays out his ambitious plans for the future.

IV1706_Fortress_1200x675

"We wanted to do a lot quickly," Fortress Biotech Inc. CEO Lindsay Rosenwald, MD, says over the boardroom table in the company's glass-enclosed top-floor conference room overlooking Manhattan's meatpacking district. The longtime life science investor's idea of doing a lot quickly? Launching nine biotech subsidiaries in less than three years, all under the Fortress umbrella.

Rosenwald has big plans for the future of Fortress too: establishing more subsidiaries, progressing pipeline drugs through clinical development and...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo